{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:30:11Z","timestamp":1758814211450},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.eururo.2009.04.041","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T08:45:36Z","timestamp":1241426736000},"page":"257-258","source":"Crossref","is-referenced-by-count":8,"title":["Is Intravesical Bacillus Calmette-Gu\u00e9rin Better than Mitomycin for Intermediate-Risk Bladder Cancer?"],"prefix":"10.1016","volume":"56","author":[{"given":"Guido","family":"Dalbagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.04.041_bib1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib3","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.04.041_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1464-410X.1985.tb07031.x","article-title":"The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer: an MRC study","volume":"57","year":"1985","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s002800050448","article-title":"Thiotepa pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour","volume":"38","author":"Masters","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eururo.2009.04.041_bib8","first-page":"139","article-title":"Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine","volume":"4","author":"Gao","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2009.04.041_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2009.04.041_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.041_bib11","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809004989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809004989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T20:26:04Z","timestamp":1558297564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809004989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0302283809004989"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.04.041","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}